Cambrex Keeps Focus on Small Molecules
Cambrex CEO Steve Klosk looks to higher valued-added segments such as high-potency actives, controlled substances, and drug-delivery technologies to drive growth.
Informex Report: Contract Manufacturers Expand
Several contract manufacturers announced capacity and service expansions at InformEx, the exhibition of custom and batch manufacturers, held in San Francisco, last week.
Implications of the Pending Pfizer-Wyeth Mega Merger
The pending merger of Pfizer and Wyeth provides Pfizer with greater strategic diversification, particularly in biologics, but only minimally addresses its generics exposure in the near term.
Survival of the Fittest Companies
The financial crisis could lead to consolidation in the contract services industry.
